CD19 and acute lymphoblastic leukemia: Albeit with a different genome-editing technology, good responses were seen with the anti-CD19 allo CAR-T-cell PBCAR0191 (azercabtagene zapreleucel) following an enhanced lymphodepletion chemotherapy regimen in B-ALL and B-NHL.